Showing results (1741-1750 of 3,072) with videos related to
Sort By:
Pageof 308
Chemotherapy|September 4, 1999
On the inhibitory activities of a new boron compound and ultrasound against the mouse ascites tumourP Sur, P Ghosh, S P Bag, et al.Chemotherapy|September 4, 1999
Adequate macrolide treatment schedules for uterine cervicitis caused by Chlamydia trachomatisH Mikamo, Y Sato, Y Hayasaki, et al.Chemotherapy|July 8, 1999
Minimum inhibitory and minimal lethal concentration against Chlamydia trachomatis dependent on the time of addition and the duration of the presence of antibioticsT Notomi, Y Ikeda, A NagayamaChemotherapy|July 8, 1999
Killing of gram-negative bacteria by ciprofloxacin within both healthy human neutrophils and neutrophils with inactivated O2-dependent bactericidal mechanismsE Cantón, J Peman, E Cabrera, et al.Chemotherapy|July 8, 1999
Nitazoxanide, a nitrothiazolide antiparasitic drug, is an anti-Helicobacter pylori agent with anti-vacuolating toxin activityY Yamamoto, A Hakki, H Friedman, et al.Chemotherapy|July 8, 1999
Clinical efficacy of amphotericin B colloidal dispersion against infections caused by Candida sppB DupontChemotherapy|July 8, 1999
Clinical efficacy of amphotericin B colloidal dispersion against infections caused by Aspergillus sppM GurwithChemotherapy|July 8, 1999
The population pharmacokinetics of amphotericin B colloidal dispersion in patients receiving bone marrow transplantsM A Amantea, R A Bowden, A Forrest, et al.Chemotherapy|May 4, 1999
Phase I pharmacokinetic study of a new 3-azinomethyl-rifamycin (rifametane) as compared to rifampicinC Potkar, N Gogtay, P Gokhale, et al.Chemotherapy|May 4, 1999
In vitro activities of pazufloxacin, a novel injectable quinolone, against bacteria causing infections in obstetric and gynecological patientsH Mikamo, Y Sato, Y Hayasaki, et al.Pageof 308